Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Japan Convenes Diet Session; Bill Submission Planned to Amend Infectious Disease Act, Medical Care Act
Japan’s Diet convened an extraordinary session on October 3 for a 69-day run through December 10. The government plans to submit a comprehensive bill to amend the Infectious Disease Act and other health-related acts. In a policy speech to kick…
To read the full story
Related Article
- Japan Enacts Bill to Amend Infectious Disease Act
December 5, 2022
- Bill to Amend Infectious Disease Act and Other Laws Enter Diet Deliberations
October 26, 2022
- Japan Cabinet OKs Bill to Amend Infectious Disease Act, Other Laws
October 11, 2022
- LDP OKs Draft Bill to Amend Infectious Disease Act to Enable Requests for Vaccine Production Boost in Emergencies
September 21, 2022
- MHLW to Submit Bill for Integrating Drug Supply Info in Extraordinary Diet Session: Official
September 15, 2022
REGULATORY
- MHLW Issues Q&A on Conditional Approval System
May 1, 2026
- Panel Backs Proposal to Allow Antibody Drugs Like Beyfortus in NIP
May 1, 2026
- METI Clarifies Naphtha Comments, Reaffirms Medical Priority
April 30, 2026
- Japan Minister Rules Out Full Self-Pay for OTC-Like Drugs
April 30, 2026
- Govt’s Bio-WG Wraps Up Biopharma Investment Roadmap Draft
April 30, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…